| Outcome Measures: |
Primary: Change in kidney function as measured by eGFR, eGFR will be measured by blood test, Baseline, 6 months, 9 months, 12 months and 18 months|Change in kidney function as measured by albuminuria, Albuminuria will be measured by urine Albumin/Creatinine Ratio, Baseline, 6 months, 9 months, 12 months and 18 months|Change in cardiac structure, Cardiac structure as measured by the 3D echocardiogram, Baseline, month 9 and month15|Change in blood insulin level, Blood insulin level will be determined lab values, Baseline, month 6 and month 18|Change in fasting blood sugar, Fasting Blood sugar will be determined lab values, Baseline, month 6 and month 18|Number of Urinary Tract infections, Data to be gathered from chart review and patient report, up to 18 months|Number of Genital infections, Data to be gathered from chart review and patient report, up to 18 months | Secondary: Change in kidney biopsy as measured by percentage of interstitial fibrosis, Baseline and 6 months|Changes in Hemoglobin A1C as measured by blood work, Baseline, Months 3,6,9,12,15 and 18 | Other: Adverse events will be collected form the medical record and patient report, up to 18 months
|
